aluates Reports

$ 0.0

Automative

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-34S5954

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Insights Forecast to 2028

BUY CHAPTERS

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2025

Code: QYRE-Auto-34S5954

Report

January 2025

Pages:82

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Achillion Pharmaceuticals Inc

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Apellis Pharmaceuticals Inc

F Hoffmann La Roche Ltd

ISU ABXIS Co Ltd

Novartis

NovelMed Therapeutics Inc

Omeros Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regenesance BV

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size

The global market for Paroxysmal Nocturnal Hemoglobinuria Treatment was valued at US$ 3642 million in the year 2024 and is projected to reach a revised size of US$ 6393 million by 2031, growing at a CAGR of 8.5% during the forecast period.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.

The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Paroxysmal Nocturnal Hemoglobinuria Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report

Report Metric	Details
Report Name	Paroxysmal Nocturnal Hemoglobinuria Treatment Market
Accounted market size in year	US$ 3642 million
Forecasted market size in 2031	US$ 6393 million
CAGR	8.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	ACH-4471 ALN-CC5 ALXN-1210 AMY-101 APL-2 Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Apellis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenesance BV
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Paroxysmal Nocturnal Hemoglobinuria Treatment Market growing?

Ans: The Paroxysmal Nocturnal Hemoglobinuria Treatment Market witnessing a CAGR of 8.5% during the forecast period 2025-2031.

What is the Paroxysmal Nocturnal Hemoglobinuria Treatment Market size in 2031?

Ans: The Paroxysmal Nocturnal Hemoglobinuria Treatment Market size in 2031 will be US$ 6393 million.

Who are the main players in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report?

Ans: The main players in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market are Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Apellis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenesance BV

What are the Application segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report?

Ans: The Applications covered in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report?

Ans: The Types covered in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report are ACH-4471, ALN-CC5, ALXN-1210, AMY-101, APL-2, Others

Recommended Reports

Blood Disorders Treatment

Lymphoma & Malignancies

Rare Disease Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 ACH-4471

1.2.3 ALN-CC5

1.2.4 ALXN-1210

1.2.5 AMY-101

1.2.6 APL-2

1.2.7 Others

1.3 Market by Application

1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2020-2031)

2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Region

2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Region (2020-2025)

2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031)

2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics

2.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends

2.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers

2.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges

2.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue

3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2020-2025)

3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue

3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio

3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024

3.5 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment Head office and Area Served

3.6 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application

3.7 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type

4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2020-2025)

4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031)

5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application

5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2020-2025)

5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)

6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)

6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)

7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)

7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)

8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)

9.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)

9.4 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2020-2031)

10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Achillion Pharmaceuticals Inc

11.1.1 Achillion Pharmaceuticals Inc Company Details

11.1.2 Achillion Pharmaceuticals Inc Business Overview

11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.1.5 Achillion Pharmaceuticals Inc Recent Development

11.2 Akari Therapeutics Plc

11.2.1 Akari Therapeutics Plc Company Details

11.2.2 Akari Therapeutics Plc Business Overview

11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.2.5 Akari Therapeutics Plc Recent Development

11.3 Alexion Pharmaceuticals Inc

11.3.1 Alexion Pharmaceuticals Inc Company Details

11.3.2 Alexion Pharmaceuticals Inc Business Overview

11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.3.5 Alexion Pharmaceuticals Inc Recent Development

11.4 Alnylam Pharmaceuticals Inc

11.4.1 Alnylam Pharmaceuticals Inc Company Details

11.4.2 Alnylam Pharmaceuticals Inc Business Overview

11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.4.5 Alnylam Pharmaceuticals Inc Recent Development

11.5 Amgen Inc

11.5.1 Amgen Inc Company Details

11.5.2 Amgen Inc Business Overview

11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.5.5 Amgen Inc Recent Development

11.6 Apellis Pharmaceuticals Inc

11.6.1 Apellis Pharmaceuticals Inc Company Details

11.6.2 Apellis Pharmaceuticals Inc Business Overview

11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.6.5 Apellis Pharmaceuticals Inc Recent Development

11.7 F. Hoffmann-La Roche Ltd

11.7.1 F. Hoffmann-La Roche Ltd Company Details

11.7.2 F. Hoffmann-La Roche Ltd Business Overview

11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.7.5 F. Hoffmann-La Roche Ltd Recent Development

11.8 ISU ABXIS Co Ltd

11.8.1 ISU ABXIS Co Ltd Company Details

11.8.2 ISU ABXIS Co Ltd Business Overview

11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.8.5 ISU ABXIS Co Ltd Recent Development

11.9 Novartis AG

11.9.1 Novartis AG Company Details

11.9.2 Novartis AG Business Overview

11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.9.5 Novartis AG Recent Development

11.10 NovelMed Therapeutics Inc

11.10.1 NovelMed Therapeutics Inc Company Details

11.10.2 NovelMed Therapeutics Inc Business Overview

11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.10.5 NovelMed Therapeutics Inc Recent Development

11.11 Omeros Corp

11.11.1 Omeros Corp Company Details

11.11.2 Omeros Corp Business Overview

11.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.11.5 Omeros Corp Recent Development

11.12 Ra Pharmaceuticals Inc

11.12.1 Ra Pharmaceuticals Inc Company Details

11.12.2 Ra Pharmaceuticals Inc Business Overview

11.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.12.5 Ra Pharmaceuticals Inc Recent Development

11.13 Regeneron Pharmaceuticals Inc

11.13.1 Regeneron Pharmaceuticals Inc Company Details

11.13.2 Regeneron Pharmaceuticals Inc Business Overview

11.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.13.5 Regeneron Pharmaceuticals Inc Recent Development

11.14 Regenesance BV

11.14.1 Regenesance BV Company Details

11.14.2 Regenesance BV Business Overview

11.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction

11.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

11.14.5 Regenesance BV Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Achillion Pharmaceuticals Inc

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Apellis Pharmaceuticals Inc

F Hoffmann La Roche Ltd

ISU ABXIS Co Ltd

Novartis

NovelMed Therapeutics Inc

Omeros Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regenesance BV

List of Tables

Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of ACH-4471

Table 3. Key Players of ALN-CC5

Table 4. Key Players of ALXN-1210

Table 5. Key Players of AMY-101

Table 6. Key Players of APL-2

Table 7. Key Players of Others

Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2025)

Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2026-2031)

Table 14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends

Table 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers

Table 16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges

Table 17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints

Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2020-2025)

Table 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)

Table 21. Ranking of Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Headquarters and Area Served

Table 24. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Product and Application

Table 25. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Treatment, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2020-2025)

Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2026-2031)

Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2020-2025)

Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2026-2031)

Table 35. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 50. Achillion Pharmaceuticals Inc Company Details

Table 51. Achillion Pharmaceuticals Inc Business Overview

Table 52. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 53. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 54. Achillion Pharmaceuticals Inc Recent Development

Table 55. Akari Therapeutics Plc Company Details

Table 56. Akari Therapeutics Plc Business Overview

Table 57. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 58. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 59. Akari Therapeutics Plc Recent Development

Table 60. Alexion Pharmaceuticals Inc Company Details

Table 61. Alexion Pharmaceuticals Inc Business Overview

Table 62. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 63. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 64. Alexion Pharmaceuticals Inc Recent Development

Table 65. Alnylam Pharmaceuticals Inc Company Details

Table 66. Alnylam Pharmaceuticals Inc Business Overview

Table 67. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 68. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 69. Alnylam Pharmaceuticals Inc Recent Development

Table 70. Amgen Inc Company Details

Table 71. Amgen Inc Business Overview

Table 72. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 73. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 74. Amgen Inc Recent Development

Table 75. Apellis Pharmaceuticals Inc Company Details

Table 76. Apellis Pharmaceuticals Inc Business Overview

Table 77. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 78. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 79. Apellis Pharmaceuticals Inc Recent Development

Table 80. F. Hoffmann-La Roche Ltd Company Details

Table 81. F. Hoffmann-La Roche Ltd Business Overview

Table 82. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 83. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 84. F. Hoffmann-La Roche Ltd Recent Development

Table 85. ISU ABXIS Co Ltd Company Details

Table 86. ISU ABXIS Co Ltd Business Overview

Table 87. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 88. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 89. ISU ABXIS Co Ltd Recent Development

Table 90. Novartis AG Company Details

Table 91. Novartis AG Business Overview

Table 92. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 93. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 94. Novartis AG Recent Development

Table 95. NovelMed Therapeutics Inc Company Details

Table 96. NovelMed Therapeutics Inc Business Overview

Table 97. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 98. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 99. NovelMed Therapeutics Inc Recent Development

Table 100. Omeros Corp Company Details

Table 101. Omeros Corp Business Overview

Table 102. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 103. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 104. Omeros Corp Recent Development

Table 105. Ra Pharmaceuticals Inc Company Details

Table 106. Ra Pharmaceuticals Inc Business Overview

Table 107. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 108. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 109. Ra Pharmaceuticals Inc Recent Development

Table 110. Regeneron Pharmaceuticals Inc Company Details

Table 111. Regeneron Pharmaceuticals Inc Business Overview

Table 112. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 113. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 114. Regeneron Pharmaceuticals Inc Recent Development

Table 115. Regenesance BV Company Details

Table 116. Regenesance BV Business Overview

Table 117. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product

Table 118. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025) & (US$ Million)

Table 119. Regenesance BV Recent Development

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

Table 123. Authors List of This Report

List of Figures

Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Picture

Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2024 VS 2031

Figure 4. ACH-4471 Features

Figure 5. ALN-CC5 Features

Figure 6. ALXN-1210 Features

Figure 7. AMY-101 Features

Figure 8. APL-2 Features

Figure 9. Others Features

Figure 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2024 VS 2031

Figure 12. Hospital Case Studies

Figure 13. Clinic Case Studies

Figure 14. Others Case Studies

Figure 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered

Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region: 2024 VS 2031

Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2024

Figure 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2024

Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)

Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)

Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2020-2031)

Figure 36. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)

Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2020-2031)

Figure 48. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 52. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 53. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 54. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 55. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 56. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 57. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 58. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 59. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 60. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 61. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 62. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 63. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 64. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hemoglobinopathy Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chronic Kidney Disease Drugs Market Research Report 2025

Global Hemophilia A Drug Market Research Report 2024

Postpartum Hemorrhage PPH Treatment Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Still s Disease Treatment Market Research Report 2025

Global Kidney Cancer Diagnosis Market Research Report 2025

Global Medicines for Alzheimer Disease Treatment Market Research Report 2025

Global Treatment Planning Software Market Research Report 2025

Global Insomnia Pharmacological Treatment Market Research Report 2025

Global Sleeping Pills Prescription Drugs Market Research Report 2025

Global Aquaculture Bacterial Diagnosis Market Research Report 2025

Global Hydroxypropyl Cellulose HPC for Pharmaceutical Market Research Report 2024

Global Diagnostic Guidewire Market Research Report 2024

Global Sleeping Pills Market Research Report 2025

Global Drug Safety and Pharmacovigilance Service Market Research Report 2025

Global Autoimmune Diseases Treatment Market Research Report 2024

Global Reproductive and Fertility Diagnosis Market Research Report 2025

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19Z7671

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10V14317

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10O5919

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4I19963

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions